Alzheimer’s Benefits Continue With Donanemab for 3 Years, Long-Term Data Show

(MedPage Today) — TORONTO — The clinical benefits of donanemab (Kisunla) continued over 3 years in people with early symptomatic Alzheimer’s disease, data from the long-term extension of the TRAILBLAZER-ALZ 2 trial suggested.
Compared with…